8-KItem 1.01 · Material AgreementItem 9.01 · Financial Statements

Abbott ($ABT) filed an 8-K on Feb 26, 2026 — added Exhibit 1.1 (Pricing Agreement) and XBRL cover page.

Filed with the SEC on February 26, 2026 · Summarized by InvestorsBot

Abbott ($ABT) filed an 8-K on Feb 26, 2026 — added Exhibit 1.1 (Pricing Agreement) and XBRL cover page. Disclosure points to an expected closing of a Notes offering and use of proceeds tied to the proposed acquisition of Exact Sciences. 📄💰 #M&A #DebtOffering

8-K contains forward-looking statements about the Exact Sciences deal and the Notes offering, cautions on material risks and directs investors to the Prospectus Supplement and Abbott’s 2025 Form 10‑K. Signed by CFO Philip P. Boudreau (Feb 26, 2026). $ABT 🔎 #Investing #Risk

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from ABBOTT LABORATORIES

Abbott (via Badger Merger Sub I) has an Agreement & Plan of Merger with Exact Sciences dated Nov 19, 2025…

8-K · March 23, 2026

Abbott ($ABT) closed its acquisition of Exact Sciences ($EXAS) on Mar 23, 2026.

8-K · March 23, 2026

Abbott filed an 8‑K (Item 9.01) on Mar 9, 2026 furnishing an indenture and note forms for debt: Floating…

8-K · March 9, 2026

Abbott Labs 8‑K filed 2026‑03‑09: Item 2.03 simply incorporates Item 1.01 by reference — it does not…

8-K · March 9, 2026

BREAKING: Abbott completes $20B senior notes offering to fund the Exact Sciences takeover — $ABT $EXAS…

8-K · March 9, 2026

BREAKING: $ABT confirms a $20B senior notes offering to fund the Exact Sciences acquisition 🚨💵 Pricing…

8-K · February 26, 2026